Back to Journals » Medical Devices: Evidence and Research » Volume 9

The activL® Artificial Disc: a next-generation motion-preserving implant for chronic lumbar discogenic pain

Authors Yue J, Garcia R, Miller LE

Received 22 December 2015

Accepted for publication 18 February 2016

Published 10 May 2016 Volume 2016:9 Pages 75—84

DOI https://doi.org/10.2147/MDER.S102949

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser

James J Yue,1 Rolando Garcia Jr,2 Larry E Miller3
 
1Department of Orthopaedic Surgery, Yale School of Medicine, New Haven, CT, 2Orthopedic Care Center, Miami, FL, 3Miller Scientific Consulting, Inc., Asheville, NC, USA

Abstract: Degeneration of the lumbar intervertebral discs is a leading cause of chronic low back pain in adults. Treatment options for patients with chronic lumbar discogenic pain unresponsive to conservative management include total disc replacement (TDR) or lumbar fusion. Until recently, only two lumbar TDRs had been approved by the US Food and Drug Administration - the Charité Artificial Disc in 2004 and the ProDisc-L Total Disc Replacement in 2006. In June 2015, a next-generation lumbar TDR received Food and Drug Administration approval - the activL® Artificial Disc (Aesculap Implant Systems). Compared to previous-generation lumbar TDRs, the activL® Artificial Disc incorporates specific design enhancements that result in a more precise anatomical match and allow a range of motion that better mimics the healthy spine. The results of mechanical and clinical studies demonstrate that the activL® Artificial Disc results in improved mechanical and clinical outcomes versus earlier-generation artificial discs and compares favorably to lumbar fusion. The purpose of this report is to describe the activL® Artificial Disc including implant characteristics, intended use, surgical technique, postoperative care, mechanical testing, and clinical experience to date.

Keywords: activL® Artificial Disc, artificial disc, degenerative disc disease, discogenic, implant, lumbar, motion preservation, pain

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Bone-anchored annular closure following lumbar discectomy reduces risk of complications and reoperations within 90 days of discharge [Corrigendum]

Klassen PD, Bernstein DT, Köhler HP, Arts MP, Weiner BK, Miller LE, Thomé C

Journal of Pain Research 2017, 10:2739-2740

Published Date: 6 December 2017

Bone-anchored annular closure following lumbar discectomy reduces risk of complications and reoperations within 90 days of discharge

Klassen PD, Bernstein DT, Köhler HP, Arts MP, Weiner B, Miller LE, Thomé C

Journal of Pain Research 2017, 10:2047-2055

Published Date: 26 August 2017

Multiexpandable cage for minimally invasive posterior lumbar interbody fusion

Coe JD, Zucherman JF, Kucharzyk DW, Poelstra KA, Miller LE, Kunwar S

Medical Devices: Evidence and Research 2016, 9:341-347

Published Date: 28 September 2016

Unraveling the confusion behind hyaluronic acid efficacy in the treatment of symptomatic knee osteoarthritis

Miller LE, Altman RD, McIntyre LF

Journal of Pain Research 2016, 9:421-423

Published Date: 17 June 2016

Clinical and radiographic outcomes with L4–S1 axial lumbar interbody fusion (AxiaLIF) and posterior instrumentation: a multicenter study

Tobler WD, Melgar MA, Raley TJ, Anand N, Miller LE, Nasca RJ

Medical Devices: Evidence and Research 2013, 6:155-161

Published Date: 18 September 2013

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012